Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2 (MT-ND2) is a protein-coding gene that forms a core component of mitochondrial respiratory chain complex I (NADH:ubiquinone oxidoreductase). Located in the inner mitochondrial membrane, MT-ND2 is essential for electron transfer from NADH to ubiquinone, a key step in the mitochondrial electron transport chain, supporting ATP synthesis via oxidative phosphorylation. Pathogenic mutations in MT-ND2 are causally linked to several mitochondrial disorders, especially Leber hereditary optic neuropathy and complex I deficiency, and are implicated as genetic modifiers in a variety of other diseases, including some cancers and neurodegenerative conditions[1][2][3][4][7].
Not directly targeted by pharmaceuticals; mechanistic disruption or mutation affects electron transport, leading to mitochondrial dysfunction
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2 (MT-ND2).